Neuropathic pain management: a focused review of current treatments and novel data from main ongoing clinical trials [0.03%]
神经痛治疗：目前治疗方法及主要临床试验新数据的集中回顾
Nikola Andrejic,Ivo Božovic,Hadi Moradi et al.
Nikola Andrejic et al.
Introduction: Neuropathic pain (NP) remains a significant challenge in clinical practice, requiring a sophisticated pharmacotherapeutic strategy for effective symptom management. This review provides a comprehensive analy...
Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma [0.03%]
揭开派姆单抗联合恩福单抗维多汀在尿路上皮癌患者中发挥活性的作用机制
Matteo Santoni,Alessandro Rizzo,Francesco Massari
Matteo Santoni
Introduction: Urothelial carcinoma (UC) is frequently associated with a poor prognosis in patients with advanced disease. A strong biological rationale supports the investigation of combining antibody-drug conjugates (ADC...
Pancreatic Ductal Adenocarcinoma (PDAC): Clinical Progress in the Last Five Years [0.03%]
胰腺导管腺癌（PDAC）：最近五年在临床上的进展
Osama M Mosalem,Ahmed AbdelHakeem,Nayef H Abdel-Razeq et al.
Osama M Mosalem et al.
Introduction: Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy with limited therapeutic options and poor overall survival. In recent years, advances in genomic profiling have revealed the complex...
Pepinemab: a SEMA4D antagonist for treatment of Huntington's and other neurodegenerative diseases [0.03%]
Pepinemab：一种用于治疗亨廷顿病及其他神经退行性疾病的SEMA4D拮抗剂
Andrew Feigin,Elizabeth E Evans,Terrence L Fisher et al.
Andrew Feigin et al.
Introduction: Huntington's Disease (HD) is a progressive fatal neurodegenerative disease with an unmet need for disease-modifying therapies. Neuroinflammation, particularly astrogliosis, plays a crucial role in the pathog...
Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents [0.03%]
青光眼的试验性药物：临床前药物的新机制方法
Murat Irkec,Anastasios G Konstas,Gábor Holló et al.
Murat Irkec et al.
Introduction: Glaucoma is a neurodegenerative disease that causes irreversible blindness worldwide. It results from retinal ganglion cell (RGC) loss and progressive optic nerve damage, mainly associated with elevated intr...
Ongoing phase 2 agents for multiple sclerosis: could we break the phase 3 trial deadlock? [0.03%]
用于多发性硬化症的二期药物展望：我们能否打破三期试验的僵局？
Silvia Susin-Calle,Jose Enrique Martinez-Rodriguez,Elvira Munteis et al.
Silvia Susin-Calle et al.
Introduction: Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system. While disease-modifying therapies have significantly improved the management of relapsing MS, pr...
Charbel Soueidy,Jean-Marie Michot,Vincent Ribrag
Charbel Soueidy
Introduction: Mantle cell lymphomais still a lymphoma subtype with productive clinical research. Recent published data on Bruton kinase inhibitors have changed the managementof patients. ...
Clinical development of BPS804 for osteogenesis imperfecta: from failure to fruition? [0.03%]
BPS804的临床开发用于骨形成不全症：从失败到成功？
Roland Chapurlat
Roland Chapurlat
Evaluation of pharmacokinetic and pharmacodynamic similarity of an IDegAsp biosimilar versus the originator in healthy Chinese volunteers [0.03%]
一种IDegAsp类似物与原研药在中国健康志愿者中的药代动力学和药效学相似性评价
Hui Liu,Yang Xiong,Xinlei Chen et al.
Hui Liu et al.
Objectives: 22011 is an insulin degludec/insulin aspart co-formulation (IDegAsp) that shares an identical amino acid sequence with Ryzodeg, the originator IDegAsp. This study aimed to compare the pharmacokinetics (PK), ph...
CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation [0.03%]
抗CD38单克隆抗体felzartamab治疗难治性抗体介导的排斥反应：一项II期临床药物评价
Katharina A Mayer,Klemens Budde,Martina Schatzl et al.
Katharina A Mayer et al.
Introduction: Felzartamab is a novel, fully human CD38 monoclonal antibody, currently in development for the treatment of antibody-mediated rejection (AMR) following kidney transplantation. ...